Cybin (NEOE:CYBN) - Stock Price, News & Analysis

CYBN Stock Overview

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics.

CYBN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.2% below our estimate of its fair value

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Cybin Inc. Competitors

Small Pharma

TSXV:DMT

CA$50.4m

Cardiol Therapeutics

TSX:CRDL

CA$163.9m

Aurora Cannabis

TSX:ACB

CA$499.6m

Cipher Pharmaceuticals

TSX:CPH

CA$204.9m

Price History & Performance

Summary of all time highs, changes and price drops for Cybin
Historical stock prices
Current Share Price	US$0.46
52 Week High	US$0.98
52 Week Low	US$0.30
Beta	0.96
1 Month Change	-19.30%
3 Month Change	-5.15%
1 Year Change	13.58%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-51.06%

Recent updates

Shareholder Returns

	CYBN	CA Pharmaceuticals	CA Market
7D	-11.5%	-3.6%	0.7%
1Y	13.6%	54.7%	5.5%

Return vs Industry: CYBN underperformed the Canadian Pharmaceuticals industry which returned 54.7% over the past year.

Return vs Market: CYBN exceeded the Canadian Market which returned 5.5% over the past year.

Price Volatility

Is CYBN's price volatile compared to industry and market?
CYBN volatility
CYBN Average Weekly Movement	13.7%
Pharmaceuticals Industry Average Movement	13.8%
Market Average Movement	9.1%
10% most volatile stocks in CA Market	18.2%
10% least volatile stocks in CA Market	3.0%

Stable Share Price: CYBN's share price has been volatile over the past 3 months.

Volatility Over Time: CYBN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

Founded	Employees	CEO	Website
n/a	50	Doug Drysdale	www.cybin.com

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.

Cybin Inc. Fundamentals Summary

How do Cybin's earnings and revenue compare to its market cap?
CYBN fundamental statistics
Market cap	CA$359.30m
Earnings (TTM)	-CA$70.45m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.1x

P/E Ratio

Is CYBN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYBN income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$70.45m
Earnings	-CA$70.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.093
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CYBN perform over the long term?

See historical performance and comparison

CYBN Stock Overview

Rewards

Risk Analysis

Cybin Inc. Competitors

TSXV:DMT

CA$50.4m

TSX:CRDL

CA$163.9m

TSX:ACB

CA$499.6m

TSX:CPH

CA$204.9m

Price History & Performance

Recent News & Updates

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Recent updates

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought CA$73k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022

Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress

Chief Operating Officer recently bought CA$123k worth of stock